MK 212 hydrochloride

Pricing Availability   Qty
Cat.No. 0941 - MK 212 hydrochloride | C8H11ClN4.HCl | CAS No. 61655-58-1
Description: 5-HT2C agonist
Chemical Name: 6-Chloro-2-(1-piperazinyl)pyrazine hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations (6)
Reviews
Literature (4)

Biological Activity

5-HT receptor agonist; displays selectivity for 5-HT2C over 5-HT2A (IC50 values are 0.028 and 0.42 μM for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively).

Technical Data

M. Wt 235.12
Formula C8H11ClN4.HCl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 61655-58-1
PubChem ID 198421
InChI Key PFIZGLUIYAZQFU-UHFFFAOYSA-N
Smiles ClC1=CN=CC(N2CCNCC2)=N1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 11.76 50 with gentle warming

Preparing Stock Solutions

The following data is based on the product molecular weight 235.12. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.5 mM 8.51 mL 42.53 mL 85.06 mL
2.5 mM 1.7 mL 8.51 mL 17.01 mL
5 mM 0.85 mL 4.25 mL 8.51 mL
25 mM 0.17 mL 0.85 mL 1.7 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Conn and Sanders-Bush (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors. J.Pharmacol.Exp.Ther. 242 552 PMID: 3039120

Hemrick-Luecke and Fuller (1996) Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentration by quipazine and MK-212. Eur.J.Pharmacol. 311 207 PMID: 8891601

Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-dazepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive J.Med.Chem. 56 1211 PMID: 23301527


If you know of a relevant reference for MK 212 hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all 5-HT2C Receptor Agonists

Keywords: MK 212 hydrochloride, MK 212 hydrochloride supplier, 5-HT2C, agonist, Serotonin, Receptors, 5-HT2, MK212, hydrochloride, 0941, Tocris Bioscience

6 Citations for MK 212 hydrochloride

Citations are publications that use Tocris products. Selected citations for MK 212 hydrochloride include:

Kawahara et al (2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci 28 12834 PMID: 19036977

Bigford et al (2012) 5-Hydroxytryptamine 5HT2C receptors form a protein complex with N-MthD.-aspartate GluN2A subunits and activate phosphorylation of Src protein to modulate motoneuronal depolarization. J Biol Chem 287 11049 PMID: 22291020

Murray et al (2010) Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med 16 694 PMID: 20512126

Murray et al (2011) Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol 106 925 PMID: 21653728


Do you know of a great paper that uses MK 212 hydrochloride from Tocris? Please let us know.

Reviews for MK 212 hydrochloride

There are currently no reviews for this product. Be the first to review MK 212 hydrochloride and earn rewards!

Have you used MK 212 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.